Cite
HARVARD Citation
Laubach, J. et al. (2021). Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. Lancet oncology. 22 (1), pp. 142-154. [Online].